Brachytherapy
Volume 5, Issue 4 , Pages 239-243 , October 2006

A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019

  • W. Robert Lee

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Duke University Medical Center, Science Dr., Rm. 05151, Box 3085, Morris Building, Durham, NC 27710. Tel.: +1-919-668-7342; fax: +1-919-668-7345.
    • ,
  • Kyounghwa Bae

      Affiliations

    • Department of Radiation Oncology, Radiation Therapy Oncology Group, Philadelphia, PA
    • ,
  • Colleen A. Lawton

      Affiliations

    • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI
    • ,
  • Michael T. Gillin

      Affiliations

    • Department of Radiation Oncology, MD Anderson Hospital, Houston, TX
    • ,
  • Gerard Morton

      Affiliations

    • Department of Radiation Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
    • ,
  • Selim Firat

      Affiliations

    • Albert Einstein School of Medicine, Philadelphia, PA
    • ,
  • Madhava Baikadi

      Affiliations

    • Albert Einstein School of Medicine, Philadelphia, PA
    • ,
  • Michael Kuettel

      Affiliations

    • Department of Radiation Medicine, Roswell Park Cancer Center, Buffalo, NY
    • ,
  • Kathryn Greven

      Affiliations

    • Department of Radiation Oncology, Wake Forest University, Winston-Salem, NC
    • ,
  • Howard Sandler

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

Received 5 June 2006 ,Revised 21 August 2006 ,Accepted 21 August 2006.

References 

  1. Lee WR, Moughan J, Owen JB, et al. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: A comprehensive survey of prostate brachytherapy in the United States. Cancer. 2003;98:1987–1994
  2. Critz FA, Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol. 2004;172(6 Pt 1):2232–2238
  3. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  4. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol. 2005;173:803–807
  5. Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys. 2003;57:944–952
  6. Merrick GS, Butler WM, Dorsey AT, et al. Potential role of various dosimetric quality indicators in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:717–724
  7. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  8. Stock RG, Stone NN, Lo YC, et al. Postimplant dosimetry for (125)I prostate implants: Definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys. 2000;48:899–906
  9. Nag S, Bice W, DeWyngaert K, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46:221–230
  10. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  11. Papagikos MA, deGuzman AF, Rossi PJ, et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V(100) superior to D(90)?. Brachytherapy. 2005;4:252–258
  12. Wallner K, Merrick G, True L, et al. 125I versus (103)Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297–1303
  13. Lee WR, deGuzman AF, Bare RL, et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 2000;46:83–88
  14. Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:32–43
  15. Merrick GS, Butler WM, Dorsey AT, et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2000;46:215–220
  16. Al Qaisieh B. Pre- and post-implant dosimetry: An inter-comparison between UK prostate brachytherapy centres. Radiother Oncol. 2003;66:181–183
  17. Lee WR, Roach M, Michalski J, et al. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys. 2002;54:457–461
  18. Prestidge BR, Bice WS, Kiefer EJ, et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;40:1111–1115
  19. Waterman FM, Yue N, Corn BW, et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys. 1998;41:1069–1077

 Dr. Lee is the recipient of an RSNA Educational Scholar Award for 2004–2006.

PII: S1538-4721(06)00244-3

doi: 10.1016/j.brachy.2006.08.005

Brachytherapy
Volume 5, Issue 4 , Pages 239-243 , October 2006

Article Tools

* Image Usage & Resolution